AN2 Therapeutics Q2 revenue down 45% YoY, cash runway into 2028.

• AN2 Therapeutics reports Q2 2025 financial results • Cash, cash equivalents, and investments: $71.2 million • Cash runway expected to fund operations into 2028 • Boron chemistry pipeline shows momentum • First Phase 1 cohort dosed in Chagas disease program • Collaboration with Drugs for Neglected Diseases initiative announced

AN2 Therapeutics (ANTX) has released its Q2 2025 financial results, highlighting a significant cash position and continued momentum in its boron chemistry pipeline. The company reported $71.2 million in cash, cash equivalents, and investments, extending its cash runway into 2028 [1].

Key highlights from the Q2 report include the initiation of the first Phase 1 cohort for AN2-502998 in Chagas disease, a significant milestone in the company's effort to develop innovative treatments for neglected tropical diseases [1]. Additionally, AN2 Therapeutics has announced a collaboration with the Drugs for Neglected Diseases initiative, further demonstrating its commitment to addressing global health challenges [1].

The report also indicates that the company's boron chemistry pipeline is showing strong momentum, with several programs advancing through various stages of clinical development. The company's strategic focus on neglected diseases and its commitment to operational efficiency are expected to position AN2 Therapeutics for continued growth and success in the biopharmaceutical sector.

References:
[1] https://www.stocktitan.net/news/ANTX/